Project description
Donor T cell receptors in the treatment of metastases
Recent successes in cancer immunotherapy did not result in significant progress towards a cure for patients with metastatic cancers, which often lack homogeneous highly expressed molecules to serve as targets for efficient T cell responses. The project partners recently demonstrated that donor blood is a rich source of T cell receptors (TCRs) that react to peptides from tissue-restricted proteins when presented on mismatched, foreign human leukocyte antigens. The homogeneous expression of tissue-specific antigens is usually maintained on primary tumours and metastases. The EU-funded OUTSOURCE project will explore patient T cells genetically equipped with donor TCRs (dTCR T cells) to target (reject) cancer-affected organs, including metastases. dTCR T cell therapy could treat malignancies in non-essential for survival organs, such as the prostate, or those that can be replaced by a transplant, such as bone marrow.
Fields of science
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural sciencesbiological sciencesgeneticsmutation
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesmedical biotechnologycells technologies
Programme(s)
Funding Scheme
ERC-COG - Consolidator Grant
Host institution
0313 Oslo
Norway
See on map
Beneficiaries (2)
0313 Oslo
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
0450 Oslo
See on map